CHLITINA (4137 TT)



For the month of November 2023, CHLITINA HOLDING LIMITED announced consolidated sales of NT\$423 million, with a 2% monthly increase and a 20% yearly increase. While keeping stability as our main objective, we are developing long-term strategies that will lay the foundations for future growth.

Operational Summary

- 1. For November 2023, CHLITINA reported consolidated sales of NT\$423.3m, with sales from our core business in China, the beauty salon franchise channel, contributing NT\$376.1m –or about 89%– to the total.
- Expressed in renminbi, CHLITINA's functional currency, for the month of November 2023 alone, consolidated sales reached RMB95.9m (2% MoM; 19% YoY). Sales originating from the beauty salon franchise network in mainland China contributed RMB85.2m to this monthly total.
- 3. Sales for the first eleven months of 2023 reached NT\$4,141.9m (+8% YoY), with sales in China from our core business, the beauty salon franchise channel, contributing NT\$3,743.1m to this total. Expressed in renminbi, CHLITINA's functional currency, sales for the first eleven months of 2023 reached RMB942.4m (9% YoY), with RMB851.6m originating from our mainland China operations.
- 4. In a recent report, Jing Daily, an authoritative digital publication on luxury consumer trends in China, noted that from May 2022 to April 2023, the sales of body care products on various e-commerce malls exceeded US\$7.2 billion (RMB52 billion). Searches for "body care" increased by 750% year on year in March this year, also stated Jing Daily, and searches for "facial skincare" increased by 56%. CHLITINA intends to seize the opportunities created by this "home beauty" surge and launch a new omni-channel retail brand as well as a new range of products in 2024Q2, in order to further expand the group's market share.

1. NT\$ Reporting for 4137 TT	November 2023 (NT\$m)	% MoM	% YoY
Consolidated Sales	423.3	2%	20%
Channel – Beauty Salon Franchise (mainland China)	376.1	-1%	17%
Channel – Beauty Salon Franchise (Taiwan, Vietnam, etc.)	13.1	5%	23%
Channel – Internet Retailing	17.5	81%	99%
Channel – Beauty Clinic	16.6	47%	21%
NT\$/RMB avg. exchange rate (Nov)	4.4120		

CHLITINA (4137 TT)



December 7, 2023

2. RMB Reporting for 4137 TT	November 2023 (RMBm)	% MoM	% YoY
Consolidated Sales	95.9	2%	19%
Channel – Beauty Salon Franchise	85.2	-1%	16%
(mainland China)			
Channel – Beauty Salon Franchise	2.9	5%	22%
(Taiwan, Vietnam, etc.)			
Channel – Internet Retailing	4.0	81%	99%
Channel – Beauty Clinic	3.8	47%	20%
3. TWD Reporting	Jan. to Nov. 2023 (NT\$m)	% MoM	% YoY
Consolidated Sales	4,141.9		8%
Channel – Beauty Salon Franchise	3,743.1		6%
(mainland China)			
Channel – Beauty Salon Franchise	138.5		18%
(Taiwan, Vietnam, etc.)			
Channel –Internet Retailing	93.5		82%
Channel –Beauty Clinic	166.8		59%
NT\$/RMB average exchange rate	4.3952		
4. RMB Reporting	Jan. to Nov. 2023 (RMBm)	% MoM	% YoY
Consolidated Sales	942.4		9%
Channel – Beauty Salon Franchise	851.6		6%
(mainland China)			
Channel – Beauty Salon Franchise	31.5		19%
(Taiwan, Vietnam, etc.)			
Channel –Internet Retailing	21.3		83%
Channel –Beauty Clinic	38.0		60%

5. Franchise Store Count	End of November 2023	Net Change in November	Yearly Net Increase	YoY %
Total	4881	-56	-52	-2%
China	4640	-56	-53	-2%
Taiwan	220	0	1	0%
Southeast Asia	21	0	0	0%



2023 Outlook and Targets

- ♦ Returning to our core business for stable growth, we will actively recruit new franchisees and increase same store performance: In 2023, we are giving ourselves the target of adding 400 stores to the CHLITINA beauty salon franchise network. Meanwhile, the RnD Manicure and Eyelash franchise will be combined with the CHLITINA beauty salon franchise to create second-generation franchise stores, reinforcing brand positioning and brand image so as to reap maximum benefits.
- ♦ Aesthetic surgery clinics and anti-ageing clinics will continue to assist the main channel: Integration and redistribution of resources will continue. Operations at our 2 UPLIDER aesthetic surgery clinics and at our 2 general practice clinics (HEDENG and JINGHE clinics) will be maintained, as these clinics situated in Nanjing and Shanghai complement the beauty salon franchise.
- Brand exposure and special marketing campaigns on e-commerce platforms will help raise the brand's visibility: Our XINMEILI e-shop and TMALL Flagship Store will cooperate with our physical stores, enabling consumers to connect with us online and offline. E-commerce and beauty salons will share resources, complementing each other.
- We will strengthen the competitiveness of the group's products and develop a long-term ESG policy: We intend to strengthen R&D development, and to use our products to capture blank territories and actively increase our market share. In line with legal and social expectations, we will attach greater importance to ESG goals and strive to implement comprehensive ESG policies.

About CHLITINA

- Main Business: Skin care products. Channels: Beauty salon franchise; Self-owned medical beauty clinics; Self-owned e-shop.
- **Current Market Positioning:** Industry leader in the mid-to-high-end beauty salon franchise business.
- Current Market Focus: China (above 90% of sales).
- **Business Model:** We control R&D, manufacture, marketing and sales. We sell our CHLITINA skin care products to franchised beauty salons. In recent years, we have been working on business diversification through new strategies including creating the UPLIDER medical beauty clinics and the JINGHE and HEDENG general clinics, developing our e-commerce activities on XINMEILI and TMall, and investing in RnD Nail & Eyelash stores among other subsidiary channels.
- Brand Background: CHLITINA was created in Taiwan in 1989 by Dr. Chen Wu-kang who successfully developed skin care products based on amino acids. In 1997, CEO Joanna Chen brought the CHLITINA brand to the Chinese mainland market where its high-quality products and effective business model

CHLITINA (4137 TT)



December 7, 2023

have been keys to its remarkable success.

New Developments: In addition to operating a large beauty salon franchise, in recent years, CHLITINA has been collaborating with academic and medical circles on R&D projects regarding stem cells, as well as anti-ageing and regenerative medicine. We have also made strategic investments in the biotechnology industry. In the long term, we are confident that this strategy will inject new blood into the group.